Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer

• ClinicalTrials.gov Identifier: NCT03699033
• Recruitment Status: Withdrawn
• First Posted: October 9, 2018
• Last Update Posted: November 5, 2020
• Sponsor: Stephanie Smiddy
• Information provided by (Responsible Party): Stephanie Smiddy, University of Toledo Health Science Campus

Study Description

Brief Summary:

Single center, single arm, Phase II study designed to evaluate the feasibility of hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with 4D PET/CT-based radiation treatment planning and concurrent carboplatin and paclitaxel in Stage IIIA or Stage IIIB NSCLC subjects.

Condition or disease	Intervention/treatment	Phase
Non Small Cell Lung Cancer	Radiation: 2.5 Gy/fraction; Drug: Carboplatin; Drug: Paclitaxel	Phase 2

Detailed Description:

This study is designed to evaluate the feasibility of hypofractionated IMRT to 62.5 Gy in 25 fractions (2.5 Gy/fraction) with 4D PET/CT-based radiation treatment planning and concurrent carboplatin and paclitaxel in Stage IIIA or Stage IIIB NSCLC subjects.

Hypofractionated IMRT allows escalation of the biological effective dose (BED) to the tumor and reduces the radiation treatment duration to 5 weeks. Increasing the BED without protracting the RT course may be a more effective means of dose escalation than simply increasing the total dose but using only 2 Gy/fraction, as was tested in RTOG 0617.

Investigators require the use of advanced treatment planning techniques, including 4D CT simulation, volume delineation utilizing PET/CT to identify gross disease and IMRT to minimize the total volume of normal tissue receiving a high dose of radiation.

As minimal published work has evaluated hypofractionated RT regimens for Stage III NSCLC with concurrent chemotherapy, investigators selected a moderately escalated dose/fraction of 2.5 Gy for evaluation in combination with concurrent carboplatin and paclitaxel.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 0 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase II Trial of Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined With Carboplatin and Paclitaxel for Subjects With Stage IIIA or IIIB Non-Small Cell Lung Cancer
• Actual Study Start Date: October 1, 2018
• Actual Primary Completion Date: October 1, 2020
• Actual Study Completion Date: October 1, 2020

Arms and Interventions

Arm

Intervention/treatment

Experimental: Radiation; 2.5 Gy/Fraction

Radiation: 2.5 Gy/fraction; Hypofractionated Intensity-Modulated Radiation Therapy (IMRT) Utilizing 2.5 Gy/Fraction to PET-avid Disease Combined with Carboplatin and Paclitaxel; Drug: Carboplatin; The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively. Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation.; Drug: Paclitaxel; The doses of chemotherapy to be given concurrently with conformal radiotherapy will be weekly paclitaxel (45 mg/m2) and carboplatin (AUC=2), respectively. Consolidation chemotherapy with 2 cycles of carboplatin (AUC=6) and paclitaxel (200 mg/m2) should be administered following completion of concurrent chemoradiation.

Outcome Measures

Primary Outcome Measures :

1. Acute and late toxicities assessed based on the common toxicity criteria for adverse events version 3.0 (CTCAEv5.0) [ Time Frame: During and within 90 days of radiation therapy ]
   Acute toxicities (toxicity during and within 90 days of radiation therapy) and delayed toxicities will be measured using CTCAE criteria, version 5.0. Acute toxicities are defined as those toxicities occurring during and within 90 days from the completion of radiotherapy and delayed toxicities are those that develop at least 90 days after the last dose of radiation

Secondary Outcome Measures :

1. Progression-free survival [ Time Frame: year 0 - year 2 ]
   Progression-free survival will be measured from the last day of radiation treatment until evidence of local or distant disease progression.
2. Overall Survival [ Time Frame: year 0 - year 5 ]
   Overall survival will be measured from the last day of radiation treatment until death.
3. Local control [ Time Frame: year 0 - year 2 ]
   Assessment of local control after treatment with radiotherapy combined with Carboplatin and Placlitaxel

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Pathologically proven diagnosis of Stage IIIA or IIIB non-small cell lung cancer (NSCLC).
• Stage IIIA subjects who are considered eligible for resection following neoadjuvant chemoradiation are eligible for this study.
• No PET/CT evidence of metastatic disease.
• An MRI of the brain with contrast excluding intracranial metastatic disease (or CT with contrast if MRI is medically contraindicated). An MRI without contrast is only permitted if the subject cannot have contrast for medical reasons.
• If a pleural effusion is present, it must be tapped and confirmed to be cytologically negative. If an effusion is deemed too small to safely tap, the subject will be eligible.
• Subjects must have measurable or evaluable disease.
• No prior thoracic radiotherapy.
• Age > 18 years at time of registration.
• ECOG Performance Status of 0-2 (Karnofsky performance scale ≥ 60).
• Hgb > 9 g/dL; ANC (absolute neutrophil count) > 1500/µl; platelets > 100,000 mcL.
• Subjects must sign study-specific informed consent form prior to registration.
• Radiation therapy and chemotherapy must start within 4 weeks of study enrollment.

Exclusion Criteria:

• Evidence of severe or uncontrolled psychiatric or systemic disease (e.g., unstable or uncompensated respiratory, cardiac, hepatic, or renal disease) that would interfere with study protocol as judged by the investigator.
• Active connective tissue disorders, such as active lupus or scleroderma.
• Known Acquired Immune Deficiency (HIV (+)/AIDS).
• Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regiment to harm nursing infants. Women of childbearing potential must agree to use medically approved and adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

Contacts and Locations

Locations

United States, Ohio

University of Toledo, Eleanor N. Dana Cancer Center

Toledo, Ohio, United States, 43614

Sponsors and Collaborators

Stephanie Smiddy

More Information

• Responsible Party: Stephanie Smiddy, Investigator, University of Toledo Health Science Campus
• ClinicalTrials.gov Identifier: NCT03699033
• Other Study ID Numbers: 202923
• First Posted: October 9, 2018
• Last Update Posted: November 5, 2020
• Last Verified: October 2018

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No

Keywords provided by Stephanie Smiddy, University of Toledo Health Science Campus:

Radiation; NSCLC; Hypofractionated; Carboplatin; Paclitaxel; IMRT; Fraction; Stage III; 4D PET/CT

Additional relevant MeSH terms:

Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Paclitaxel; Carboplatin; Antineoplastic Agents, Phytogenic; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action